All companies › SOPH

SOPH · SOPHiA GENETICS SA

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells10
Research cases0
Last filing2026-10-05

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-10-05 — CARDOZA GEORGE · sold 1,592 @ $8.10 2026-10-05 — Muken Ross · sold 9,838 @ $8.13 2026-10-05 — Xu Zhenyu · sold 7,394 @ $8.12 2026-10-05 — Camblong Jurgi · sold 40,172 @ $8.13 2026-10-05 — Menu Philippe · sold 7,394 @ $8.13 2026-10-05 — Puylaert Kevin · sold 185 @ $8.06 2026-10-05 — Puylaert Kevin · sold 31 @ $7.92 2026-10-05 — Verma Abhimanyu · sold 5,284 @ $8.12 2026-10-05 — Valente Manuela · sold 4,240 @ $8.13 2026-10-05 — Van Well Daan · sold 6,168 @ $8.12
2026-10-052026-10-05

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Puylaert Kevin Chief Sales Officer
CARDOZA GEORGE Chief Financial Officer
Muken Ross Chief Executive Officer, Director
Xu Zhenyu Chief Scientific Officer
Camblong Jurgi Executive Chairman, Director
Menu Philippe Chief Medical Officer
Verma Abhimanyu Chief Technology Officer
Valente Manuela Chief People Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $SOPH is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-05', 'insider_name': 'CARDOZA GEORGE', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 1592.0, 'price': 8.1014, 'value': 12897.43, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Muken Ross', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 9838.0, 'price': 8.1288, 'value': 79971.13, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Xu Zhenyu', 'insider_title': 'Chief Scientific Officer', 'transaction_type': 'Open-market sell', 'shares': 7394.0, 'price': 8.1248, 'value': 60074.77, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Camblong Jurgi', 'insider_title': 'Executive Chairman, Director', 'transaction_type': 'Open-market sell', 'shares': 40172.0, 'price': 8.1282, 'value': 326526.05, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Menu Philippe', 'insider_title': 'Chief Medical Officer', 'transaction_type': 'Open-market sell', 'shares': 7394.0, 'price': 8.1282, 'value': 60099.91, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Puylaert Kevin', 'insider_title': 'Chief Sales Officer', 'transaction_type': 'Open-market sell', 'shares': 185.0, 'price': 8.06, 'value': 1491.1, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Puylaert Kevin', 'insider_title': 'Chief Sales Officer', 'transaction_type': 'Open-market sell', 'shares': 31.0, 'price': 7.92, 'value': 245.52, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Verma Abhimanyu', 'insider_title': 'Chief Technology Officer', 'transaction_type': 'Open-market sell', 'shares': 5284.0, 'price': 8.1243, 'value': 42928.8, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Valente Manuela', 'insider_title': 'Chief People Officer', 'transaction_type': 'Open-market sell', 'shares': 4240.0, 'price': 8.1338, 'value': 34487.31, 'is_buy': False}, {'transaction_date': '2026-10-05', 'insider_name': 'Van Well Daan', 'insider_title': 'Chief Legal Officer', 'transaction_type': 'Open-market sell', 'shares': 6168.0, 'price': 8.1226, 'value': 50100.2, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for SOPH today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.